# A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(5) 80/20/10mg

> **NCT05698043** · PHASE1 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 63 (actual)

## Conditions studied

- Hypertension and Dyslipidemia

## Interventions

- **DRUG:** CKD-386(5)
- **DRUG:** D013, D326, D337

## Key facts

- **NCT ID:** NCT05698043
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-17
- **Primary completion:** 2023-09-01
- **Final completion:** 2023-09-26
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2023-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05698043

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05698043, "A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(5) 80/20/10mg". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT05698043. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*